Valuation: Nectar Lifesciences Limited

Market Cap 1.99B 20.64M 18.33M 17.14M 15.62M 29.41M 29.82M 207M 80.29M 1.01B 77.5M 75.82M 3.25B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 736M 7.65M 6.79M 6.35M 5.79M 10.9M 11.05M 76.84M 29.74M 375M 28.71M 28.09M 1.2B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
1 day-0.19%
1 week-6.43%
Current month-0.19%
1 month-17.29%
3 months-11.33%
6 months+10.96%
Current year-47.03%
1 week 10.18
Extreme 10.18
11.19
1 month 10.18
Extreme 10.18
12.72
Current year 9.2
Extreme 9.2
20.94
1 year 9.2
Extreme 9.2
22.49
3 years 9.2
Extreme 9.2
56.39
5 years 9.2
Extreme 9.2
56.39
10 years 7.2
Extreme 7.2
56.39
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-6.43% - - 21.27M
-0.31%-2.86%+39.10%+113.29% 1,031B
-1.99%-4.09%+39.54%+67.34% 638B
-0.44%-1.70%+6.64%+75.79% 462B
-1.08%-2.90%+59.43%+40.12% 359B
-0.03%-3.96%+23.63%+40.70% 335B
-1.58%-0.76%+13.50%+26.44% 273B
-2.02%-2.97%-3.25%+9.88% 253B
-2.40%+1.41%+37.95%+54.62% 228B
-0.73%-1.20%+33.05%+99.58% 185B
Average -1.12%-0.36%+27.73%+58.64% 418.21B
Weighted average by Cap. -1.09%-0.35%+30.68%+69.99%

Financials

2025 2026
Net sales 16.7B 173M 154M 144M 131M 247M 251M 1.74B 675M 8.51B 651M 637M 27.32B -
Net income -1.14B -11.81M -10.49M -9.81M -8.94M -16.83M -17.06M -119M -45.93M -579M -44.33M -43.37M -1.86B -2.93B -30.42M -27.02M -25.27M -23.03M -43.35M -43.95M -306M -118M -1.49B -114M -112M -4.79B
Net Debt 5.62B 58.4M 51.87M 48.51M 44.2M 83.22M 84.36M 587M 227M 2.86B 219M 215M 9.2B -1.25B -12.99M -11.54M -10.79M -9.84M -18.52M -18.77M -131M -50.54M -637M -48.79M -47.73M -2.05B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
01/10/26 ₹10.33 -0.19% 3,138
30/09/26 ₹10.35 -3.36% 47,012
29/09/26 ₹10.71 -0.37% 15,661
28/09/26 ₹10.75 -0.19% 5,263
25/09/26 ₹10.77 -1.10% 24,469